2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.
作者信息
Steffel Jan, Collins Ronan, Antz Matthias, Cornu Pieter, Desteghe Lien, Haeusler Karl Georg, Oldgren Jonas, Reinecke Holger, Roldan-Schilling Vanessa, Rowell Nigel, Sinnaeve Peter, Vanassche Thomas, Potpara Tatjana, Camm A John, Heidbüchel Hein
机构信息
Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich, Switzerland.
Age-Related Health Care, Tallaght University Hospital / Department of Gerontology Trinity College, Dublin, Ireland.
出版信息
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
Abstract
摘要
相似文献
1
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.2021年欧洲心律协会心房颤动患者使用非维生素K拮抗剂口服抗凝药实用指南。
Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065.
2
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.真实世界证据比较非瓣膜性心房颤动的口服抗凝药物：系统评价和网络荟萃分析。
Future Cardiol. 2022 May;18(5):393-405. doi: 10.2217/fca-2021-0120. Epub 2022 Apr 1.
3
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.非维生素 K 拮抗剂口服抗凝剂在非瓣膜性心房颤动中预防卒中的直接比较有效性和安全性：观察性研究的系统评价和荟萃分析。
Eur J Epidemiol. 2019 Feb;34(2):173-190. doi: 10.1007/s10654-018-0415-7. Epub 2018 Jun 8.
4
Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population.医疗保险人群中从华法林转换为直接口服抗凝剂的非瓣膜性心房颤动患者的有效性和安全性
Adv Ther. 2025 Mar;42(3):1462-1483. doi: 10.1007/s12325-024-03099-y. Epub 2025 Jan 30.
5
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.依度沙班与达比加群、利伐沙班及阿哌沙班相比在预防心房颤动患者卒中方面的疗效和安全性：一项间接比较分析
Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.
6
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.非瓣膜性心房颤动患者口服抗凝剂的有效性和安全性。
Stroke. 2018 Dec;49(12):2933-2944. doi: 10.1161/STROKEAHA.118.020232.
7
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界环境中比较非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂预防心房颤动卒中：系统评价和荟萃分析。
Stroke. 2017 Sep;48(9):2494-2503. doi: 10.1161/STROKEAHA.117.017549. Epub 2017 Jul 17.
8
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation.非维生素 K 拮抗剂口服抗凝剂与苯丙香豆素在非瓣膜性心房颤动患者中的比较效果。
Int J Cardiol. 2024 Jun 1;404:131894. doi: 10.1016/j.ijcard.2024.131894. Epub 2024 Mar 2.
9
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.非维生素K拮抗剂口服抗凝药在亚洲房颤患者中的作用：一篇遵循PRISMA规范的文章。
Medicine (Baltimore). 2020 Jul 2;99(27):e21025. doi: 10.1097/MD.0000000000021025.
10
Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study.非瓣膜性心房颤动且胃肠道出血高危风险患者的口服抗凝剂的比较安全性和有效性：一项全国性法国队列研究。
PLoS One. 2024 Nov 15;19(11):e0310322. doi: 10.1371/journal.pone.0310322. eCollection 2024.
引用本文的文献
1
Oral Anticoagulant Therapy in Patients with Atrial Fibrillation After Intracranial Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.颅内出血后心房颤动患者的口服抗凝治疗：一项随机对照试验的荟萃分析
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251368889. doi: 10.1177/10760296251368889. Epub 2025 Aug 21.
2
Measurement of plasma direct oral anticoagulants concentrations in real-world clinical and laboratory settings on a 24/7 basis: a 10-year experience.在真实临床和实验室环境中全天候测量血浆直接口服抗凝剂浓度：十年经验
J Thromb Thrombolysis. 2025 Aug 19. doi: 10.1007/s11239-025-03159-2.
3
Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications.心房颤动与癌症：病理生理机制及临床意义
J Clin Med. 2025 Aug 7;14(15):5600. doi: 10.3390/jcm14155600.
4
Anti-Factor Xa Activity of Apixaban in Extremely Low Body Weight.阿哌沙班在极低体重患者中的抗Xa因子活性
J Clin Med. 2025 Jul 24;14(15):5238. doi: 10.3390/jcm14155238.
5
Practical Comprehensive Approach to Current Atrial Fibrillation Challenges: Insights from an Expert Panel.应对当前房颤挑战的实用综合方法：专家小组见解
J Clin Med. 2025 Jul 22;14(15):5199. doi: 10.3390/jcm14155199.
6
Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.抗癌药物与直接口服抗凝剂（DOAC）的药代动力学药物相互作用推荐意见的差异：不同临床决策支持系统及来源的比较分析
Pharmaceuticals (Basel). 2025 Jul 16;18(7):1044. doi: 10.3390/ph18071044.
7
Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis.直接口服抗凝剂与维生素K拮抗剂在肝病合并心房颤动患者中的有效性和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2025 Jul 14;16:1620394. doi: 10.3389/fphar.2025.1620394. eCollection 2025.
8
Identification of risk factors and development of a predictive model in patients using cefmetazole for international normalized ratio elevation.使用头孢美唑导致国际标准化比值升高的患者中危险因素的识别及预测模型的建立
PLoS One. 2025 Jul 28;20(7):e0322909. doi: 10.1371/journal.pone.0322909. eCollection 2025.
9
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients.老年住院患者中阿哌沙班血清浓度与肾功能的关系
Drugs Aging. 2025 Jul 24. doi: 10.1007/s40266-025-01232-2.
10
The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population-How to Overcome the Challenges of Geriatric Syndromes.老年人群中直接口服抗凝剂（DOACs）的应用——如何克服老年综合征带来的挑战
J Clin Med. 2025 Jun 20;14(13):4396. doi: 10.3390/jcm14134396.
本文引用的文献
1
Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19.50岁及以上成人新冠病毒病患者的心房颤动与30天内发生血栓栓塞事件的风险及死亡率
J Arrhythm. 2020 Dec 11;37(1):231-237. doi: 10.1002/joa3.12458. eCollection 2021 Feb.
2
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.随机、双盲、半剂量与全剂量依度沙班比较在 14014 例房颤患者中的应用。
J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207. doi: 10.1016/j.jacc.2020.12.053.
3
Warfarin versus direct oral anticoagulants for treating left ventricular thrombus: a systematic review and meta-analysis.华法林与直接口服抗凝剂治疗左心室血栓的系统评价和荟萃分析。
Thromb J. 2021 Feb 1;19(1):7. doi: 10.1186/s12959-021-00259-w.
4
Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.心血管疾病及危险因素对不同年龄COVID-19患者死亡结局的影响：一项系统综述与荟萃分析
Heart. 2021 Mar;107(5):373-380. doi: 10.1136/heartjnl-2020-317901. Epub 2020 Dec 17.
5
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班在心房颤动合并生物瓣二尖瓣患者中的应用。
N Engl J Med. 2020 Nov 26;383(22):2117-2126. doi: 10.1056/NEJMoa2029603. Epub 2020 Nov 14.
6
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial-The RIWA study.机械心脏瓣膜患者中利伐沙班与华法林的比较：开放性、概念验证试验——RIWA 研究。
Am J Cardiovasc Drugs. 2021 May;21(3):363-371. doi: 10.1007/s40256-020-00449-3. Epub 2020 Nov 5.
7
Direct oral anticoagulant use in left ventricular thrombus.左心室血栓中直接口服抗凝剂的应用
Thromb J. 2020 Oct 29;18:29. doi: 10.1186/s12959-020-00242-x. eCollection 2020.
8
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Atrial Fibrillation After TAVR.经导管主动脉瓣置换术（TAVR）后心房颤动患者的直接口服抗凝剂与维生素 K 拮抗剂比较。
JACC Cardiovasc Interv. 2020 Nov 23;13(22):2587-2597. doi: 10.1016/j.jcin.2020.09.013. Epub 2020 Oct 28.
9
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.双联与三联抗栓治疗用于行经皮冠状动脉介入治疗的伴有或不伴有急性冠状动脉综合征的心房颤动患者的安全性和有效性：基于新型口服抗凝剂的随机临床试验的协作荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f50-f60. doi: 10.1093/ehjcvp/pvaa116.
10
Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures.非维生素K拮抗剂口服抗凝药用于接受电生理手术的房颤患者的治疗
Eur Heart J Suppl. 2020 Sep 15;22(Suppl I):I32-I37. doi: 10.1093/eurheartj/suaa102. eCollection 2020 Sep.
Zotero 插件